174 related articles for article (PubMed ID: 16904289)
1. MAGI-3 regulates LPA-induced activation of Erk and RhoA.
Zhang H; Wang D; Sun H; Hall RA; Yun CC
Cell Signal; 2007 Feb; 19(2):261-8. PubMed ID: 16904289
[TBL] [Abstract][Full Text] [Related]
2. MAGI-3 competes with NHERF-2 to negatively regulate LPA2 receptor signaling in colon cancer cells.
Lee SJ; Ritter SL; Zhang H; Shim H; Hall RA; Yun CC
Gastroenterology; 2011 Mar; 140(3):924-34. PubMed ID: 21134377
[TBL] [Abstract][Full Text] [Related]
3. Physical and functional interactions of the lysophosphatidic acid receptors with PDZ domain-containing Rho guanine nucleotide exchange factors (RhoGEFs).
Yamada T; Ohoka Y; Kogo M; Inagaki S
J Biol Chem; 2005 May; 280(19):19358-63. PubMed ID: 15755723
[TBL] [Abstract][Full Text] [Related]
4. MAGI proteins can differentially regulate the signaling pathways of 5-HT
Hammad MM; Dunn HA; Ferguson SSG
Cell Signal; 2018 Jul; 47():109-121. PubMed ID: 29625175
[TBL] [Abstract][Full Text] [Related]
5. Lysophosphatidic acid stimulation of NHE3 exocytosis in polarized epithelial cells occurs with release from NHERF2 via ERK-PLC-PKCδ signaling.
Cha B; Chen T; Sarker R; Yang J; Raben D; Tse CM; Kovbasnjuk O; Donowitz M
Am J Physiol Cell Physiol; 2014 Jul; 307(1):C55-65. PubMed ID: 24760985
[TBL] [Abstract][Full Text] [Related]
6. NHERF2 specifically interacts with LPA2 receptor and defines the specificity and efficiency of receptor-mediated phospholipase C-beta3 activation.
Oh YS; Jo NW; Choi JW; Kim HS; Seo SW; Kang KO; Hwang JI; Heo K; Kim SH; Kim YH; Kim IH; Kim JH; Banno Y; Ryu SH; Suh PG
Mol Cell Biol; 2004 Jun; 24(11):5069-79. PubMed ID: 15143197
[TBL] [Abstract][Full Text] [Related]
7. Effect of lysophosphatidylglycerol on several signaling molecules in OVCAR-3 human ovarian cancer cells: involvement of pertussis toxin-sensitive G-protein coupled receptor.
Park KS; Kim MK; Im DS; Bae YS
Biochem Pharmacol; 2007 Mar; 73(5):675-81. PubMed ID: 17161826
[TBL] [Abstract][Full Text] [Related]
8. Proteomic analysis of beta1-adrenergic receptor interactions with PDZ scaffold proteins.
He J; Bellini M; Inuzuka H; Xu J; Xiong Y; Yang X; Castleberry AM; Hall RA
J Biol Chem; 2006 Feb; 281(5):2820-7. PubMed ID: 16316992
[TBL] [Abstract][Full Text] [Related]
9. Lysophosphatidic acid activates the RhoA and NF-κB through Akt/IκBα signaling and promotes prostate cancer invasion and progression by enhancing functional invadopodia formation.
Hwang YS; Lee J; Zhang X; Lindholm PF
Tumour Biol; 2016 May; 37(5):6775-85. PubMed ID: 26662305
[TBL] [Abstract][Full Text] [Related]
10. Unmasking of LPA1 receptor-mediated migration response to lysophosphatidic acid by interleukin-1β-induced attenuation of Rho signaling pathways in rat astrocytes.
Sato K; Horiuchi Y; Jin Y; Malchinkhuu E; Komachi M; Kondo T; Okajima F
J Neurochem; 2011 Apr; 117(1):164-74. PubMed ID: 21244430
[TBL] [Abstract][Full Text] [Related]
11. Beta-2 adrenergic receptor mediated ERK activation is regulated by interaction with MAGI-3.
Yang X; Zheng J; Xiong Y; Shen H; Sun L; Huang Y; Sun C; Li Y; He J
FEBS Lett; 2010 Jun; 584(11):2207-12. PubMed ID: 20353789
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms in LPA-induced tumor cell migration: critical role of phosphorylated ERK.
Stähle M; Veit C; Bachfischer U; Schierling K; Skripczynski B; Hall A; Gierschik P; Giehl K
J Cell Sci; 2003 Sep; 116(Pt 18):3835-46. PubMed ID: 12902401
[TBL] [Abstract][Full Text] [Related]
13. LPA-induced migration of ovarian cancer cells requires activation of ERM proteins via LPA
Park J; Jang JH; Oh S; Kim M; Shin C; Jeong M; Heo K; Park JB; Kim SR; Oh YS
Cell Signal; 2018 Apr; 44():138-147. PubMed ID: 29329782
[TBL] [Abstract][Full Text] [Related]
14. Lysophosphatidic acid 2 receptor-mediated supramolecular complex formation regulates its antiapoptotic effect.
E S; Lai YJ; Tsukahara R; Chen CS; Fujiwara Y; Yue J; Yu JH; Guo H; Kihara A; Tigyi G; Lin FT
J Biol Chem; 2009 May; 284(21):14558-71. PubMed ID: 19293149
[TBL] [Abstract][Full Text] [Related]
15. Ovarian cancer-derived lysophosphatidic acid stimulates secretion of VEGF and stromal cell-derived factor-1 alpha from human mesenchymal stem cells.
Jeon ES; Heo SC; Lee IH; Choi YJ; Park JH; Choi KU; Park DY; Suh DS; Yoon MS; Kim JH
Exp Mol Med; 2010 Apr; 42(4):280-93. PubMed ID: 20177148
[TBL] [Abstract][Full Text] [Related]
16. Role of heterotrimeric G-proteins in lysophosphatidic acid-mediated neurite retraction by RhoA-dependent and -independent mechanisms in N1E-115 cells.
Couvillon AD; Exton JH
Cell Signal; 2006 May; 18(5):715-28. PubMed ID: 16122906
[TBL] [Abstract][Full Text] [Related]
17. Lysophosphatidic acid down-regulates stress fibers and up-regulates pro-matrix metalloproteinase-2 activation in ovarian cancer cells.
Do TV; Symowicz JC; Berman DM; Liotta LA; Petricoin EF; Stack MS; Fishman DA
Mol Cancer Res; 2007 Feb; 5(2):121-31. PubMed ID: 17314270
[TBL] [Abstract][Full Text] [Related]
18. The cross talk between protein kinase A- and RhoA-mediated signaling in cancer cells.
Chen Y; Wang Y; Yu H; Wang F; Xu W
Exp Biol Med (Maywood); 2005 Nov; 230(10):731-41. PubMed ID: 16246900
[TBL] [Abstract][Full Text] [Related]
19. Betagamma subunits of G(i/o) suppress EGF-induced ERK5 phosphorylation, whereas ERK1/2 phosphorylation is enhanced.
Obara Y; Okano Y; Ono S; Yamauchi A; Hoshino T; Kurose H; Nakahata N
Cell Signal; 2008 Jul; 20(7):1275-83. PubMed ID: 18407464
[TBL] [Abstract][Full Text] [Related]
20. Lysophosphatidic acid stimulates PC-3 prostate cancer cell Matrigel invasion through activation of RhoA and NF-kappaB activity.
Hwang YS; Hodge JC; Sivapurapu N; Lindholm PF
Mol Carcinog; 2006 Jul; 45(7):518-29. PubMed ID: 16402387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
